Evidence map›Paper›PMID 34021421›Full record

ArticleNeurosurgical review2022

Paraganglioma of the cauda equina: a tertiary centre experience and scoping review of the current literature.

Anan Shtaya, Robert Iorga, Samantha Hettige, Leslie R Bridges, Simon Stapleton, Francis G Johnston

Open access · hybridAbstract readScoping Review
In one paragraph

Article in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Cauda equina neuroendocrine tumor: a case report and diagnostic update.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anan ShtayaNeurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, London, UK. Anan.Shtaya@uhs.nhs.uk.ORCID http://orcid.org/0000-0001-7459-8437
Robert IorgaAtkinson Morley Neurosurgery Centre, St George's University Hospitals NHS Foundation Trust, London, UK.
Samantha HettigeAtkinson Morley Neurosurgery Centre, St George's University Hospitals NHS Foundation Trust, London, UK.
Leslie R BridgesNeurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, London, UK.
Simon StapletonAtkinson Morley Neurosurgery Centre, St George's University Hospitals NHS Foundation Trust, London, UK.
Francis G JohnstonAtkinson Morley Neurosurgery Centre, St George's University Hospitals NHS Foundation Trust, London, UK.
St George’s University Hospitals NHS Foundation Trust · GBSt George's, University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cauda equina paragangliomas are rare benign extra-adrenal neuroendocrine tumours arising from the neural crest cells associated with autonomic ganglia. These tumours are often mistaken preoperatively for ependymomas or schwannomas. Patients present with axial or radicular pain with or without neurological deficits. Recurrence, secretory features and length of follow-up are controversial. We conducted a retrospective cohort study of paraganglioma through searching a prospectively maintained histopathology database. Patient demographics, presentation, surgery, complications, recurrence, follow-up and outcome between 2004 and 2016 were studied. The primary aim was to collate and describe the current evidence base for recurrence and secretory features of the tumour. The secondary objective was to report outcome and follow-up strategy. A scoping review was performed in accordance with the PRISMA-ScR Checklist. Ten patients were diagnosed (M:F 7:3) with a mean age of 53.6 ± 5.1 (range 34-71 years). MRI scans revealed intradural lumbar enhancing lesions. All patients had complete microsurgical excisions without adjuvant therapy with no recurrence with a mean follow-up of 5.1 ± 1.4 years. Tumours were attached to the filum terminale. Electron microscopic images demonstrated abundant neurosecretory granules with no evidence of catecholamine production. A total of 620 articles were screened and 65 papers (including ours) combining 121 patients (mean age 48.8 and M:F 71:50) were included. The mean follow-up was 3.48 ± 0.46 (range 0.15-23 years). Back pain was the most common symptom (94%). Cure following surgery was achieved in 93% of the patients whilst 7% had recurrence. Total resection likely results in cure without the need for adjuvant therapy or prolonged follow-up. However, in certain situations, the length of follow-up should be determined by the treating surgeon.

Indexed as

Cauda EquinaEpendymomaParagangliomaPeripheral Nervous System NeoplasmsAdultAgedHumansMagnetic Resonance ImagingMiddle AgedRetrospective StudiesCauda equinaIntraduralLumbarParagangliomaSacral

Identifiers

PMID34021421
PMCPMC8827161
OpenAlexW3160511625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.